Table 2. Primary outcome measures in the Intent-to-Treat group.
| Outcome measures | Timepoint | Education (n = 39^) | Aerobic Exercise (n = 78^) | p-value* |
|---|---|---|---|---|
| Global Amyloid Burden (SUVR) | Baseline | 1.2 (0.2) | 1.22 (0.2) | 0.93 |
| Week 52 | 1.21 (0.2) | 1.22 (0.2) | ||
| Change | 0.01 (0.04) | 0.01 (0.06) | ||
| VO2 peak (mL·kg-1·min-1) | Baseline | 22.7 (5.3) | 21.9 (5.2) | 0.01 |
| Week 52 | 23.0 (4.9) | 24.3 (5.8) | ||
| Change | 0.1 (2.5) | 2.0 (2.5) | ||
| Whole Brain Volume (mL) | Baseline | 1061.7 (114.4) | 1068.7 (109.7) | 0.12 |
| Week 52 | 1059.1 (115.1) | 1063.4 (109.1) | ||
| Change | -2.6 (-7.2) | -5.3 (-8.7) | ||
| Hippocampal Volume (mL) | Baseline | 7.6 (1.0) | 7.5 (0.8) | 0.42 |
| Week 52 | 7.6 (1.0) | 7.4 (0.8) | ||
| Change | -0.09 (0.14) | -0.07 (0.10) | ||
| Executive Function Composite | Baseline | -0.042 (0.365) | 0.029 (0.458) | 0.83 |
| Week 26 | -0.035 (0.389) | 0.017 (0.625) | ||
| Week 52 | -0.037 (0.452) | 0.018 (0.615) | ||
| Verbal Memory Composite | Baseline | 0.032 (0.822) | -0.016 (0.882) | 0.69 |
| Week 26 | -0.007 (1.014) | 0.003 (0.989) | ||
| Week 52 | 0.051 (0.939) | -0.025 (0.935) | ||
| Visuospatial Composite | Baseline | -0.062 (0.572) | 0.031 (0.646) | 0.30 |
| Week 26 | 0.012 (0.659) | -0.006 (0.715) | ||
| Week 52 | 0.003 (0.559) | -0.001 (0.643) |
Mean (standard deviation). Cognitive composites at Week 26 and Week 52 can be interpreted as change from baseline.
*2 sample paired t-test comparing baseline and week 52 for amyloid, fitness and volume measures. For cognitive measures, a p-value for treatment by time interaction test from linear mixed models is given.
^Sample size for change in amyloid is Educ:35/Exercise:74. Sample sizes for change in fitness and volumes are Educ:34/Exercise:70 Sample sizes for cognitive measures at baseline, week 26, and week 52 are Educ:39,37,36/Exercise:78,75,75. SUVR = Standard uptake value ratio; VO2 peak = peak oxygen consumption during the graded exercise test.